28 May 2024
Xeros Technology Group
plc
('Xeros' or the 'Company' or the
'Group')
FULL YEAR RESULTS 2023
Significant operational and commercial
progress
Xeros Technology Group plc (AIM: XSG), the
creator of technologies that reduce the impact of clothing on the
planet, today announces its full year results for the year ended 31
December 2023, which show the Group's licensees moving
closer to commercial launch.
Operational
highlights
·
|
Completion of technology transfer process on
IFB and Yilmak Makina with these machines now moving to the
manufacture and marketing stage
|
·
|
Expanded commercial sales team resulting in 10
new opportunities identified and the Group now in discussion with
six of the 10 leading global domestic washing machine
manufacturers
|
|
Filtration
(estimated addressable market £350m p.a.)
|
|
-
|
Two new licensing agreements with major
European component manufactures for XF1 taking the total to three
and covering 99% of the 105 million washing machines produced
annually
|
|
-
|
In negotiations to manufacture the XF3 under
licence - the new external in-line filter, XF3, was launched
successfully at IFA, the world's largest consumer electronics and
home appliances trade show in Berlin
|
|
Finish
(estimated addressable market £132m p.a.)
|
|
-
|
Following the new licensing agreement signed
with global garment-finishing machine specialists, Yilmak Makina,
and distributor, KRM, for denim processing technology,
Yilmak's Xeros-enabled denim processing machine was
successfully launched at ITMA in Milan, and will see its full
marketing launch at ITM in June
|
|
-
|
Demand side interest progressing with a
leading garment brand and a European retail chain in the process of
specifying Xeros' technology in the recipe of their core denim
ranges
|
|
-
|
Revenue streams generated from both licensing
agreement and ongoing supply of consumables - XOrb
product
|
|
Care
(estimated addressable market £3bn p.a.)
|
|
-
|
IFB Appliances' new domestic 9kg washing
machine, featuring Xeros technology to save water and prolong
garment life, moved from R&D to manufacturing and marketing
with a launch in India planned within the calendar year
|
|
-
|
Our long-standing partner in France, Georges
continues to thrive with plans to open new sites over the next
12-18 months, in line with their expansion into the laundering of
fire fighter uniforms
|
|
-
|
Georges has also received compelling feedback from
its key customer base showing uniform life extension of 20% since
using the Xeros CARE technology
|
|
|
| |
Key
financials
·
|
Revenue increased 81% to £0.3m (FY22: £0.02m) -
as a result of increased licensing revenue and sales of
XOrbs
|
·
|
The increase in revenue from high margin
licensing, has driven an increase in gross profit in the period to
£0.2m (2022: £0.1m), an increase of 81.1%, resulting in an overall
gross margin of 82.5% (2022: 51.2%).
|
·
|
The Group decreased its adjusted EBITDA loss by
37.9% to £4.6m (2022: loss £7.4m)
|
·
|
Administrative expenses decreased by 34.1% to
£5.0m (2022: £7.5m), following a reduction in the Group's headcount
and a continued focus on cost across the business
|
·
|
Net cash outflow from operations decreased by
33.2% to £4.7m (2022: £7.0m) as a result of the Group's overall
cost reduction
|
Post Period
End and Outlook
·
|
Fundraise in April 2024 and warrant redemptions
in January 2024 raised net £5.6m strengthening the Group's
balance sheet to provide working capital to support our existing
partners through to launch
|
·
|
Cost controls will remain in place and priority will
be given to the commercialisation of existing opportunities.
|
·
|
A number of our commercial partners close to
commercial scale roll-out of machines containing Xeros' IP
|
Neil Austin,
CEO said:
"Our agreements with licensees moved
closer to commercial launch, as we embarked on the crucial
technology transfer process with both IFB and Yilmak Makina. We
completed the technology transfer for IFB domestic machines (Goa)
in December 2023, and Yilmak Makina's commercial denim processing
machines (Turkey) in Q1 of the new financial year. All these
machines have now moved to the manufacture and marketing stage,
ahead of scale launch later this year.
"In addition, the work undertaken to increase the
Group's commercial focus has resulted in a stronger than expected
pipeline of potential new agreements. We are now in discussion with
10 major organisations with interest across all the Group's
technologies."
Enquiries
Xeros Technology Group
plc
Neil Austin, Chief
Executive Officer
Alex Tristram,
Director of Finance
|
Tel: 0114 269
9656
|
Cavendish Capital Markets Limited
(Nominated Adviser and Broker)
Julian Blunt/Teddy
Whiley, Corporate Finance
Andrew Burdis/Sunila
de Silva, ECM
|
Tel: 020 7220
0570
|
Belvedere
Communications
Cat
Valentine
Keeley
Clarke
|
xeros@belvederepr.com
Mob: 07715 769
078
Mob: 07967 816
525
|
|
| |
About Xeros
Xeros Technology plc has developed patented and
proven, industry-leading technologies which reduce the
environmental impact of how industries make and care for
clothes.
The traditional wet processing methods used in
industrial and domestic laundry and garment manufacturing consume
billions of litres of fresh water and large amounts of energy and
chemicals, as well as damaging and weakening clothing fibres and
creating rising levels of environmental pollution. It is estimated
that washing machines contribute 35% of the 171 trillion
microplastic particles in the ocean.
A range of actors, including consumers, the
media NGOs and regulators are exerting pressure on these
industries, with legislative action beginning to be
taken.
Xeros' three main technologies, Filtration, Finish, and Care, facilitate garment manufacturers,
industrial laundries, domestic washing machine manufacturers and
consumers, to reduce their environmental impact, whilst also
significantly improving efficiency in the process.
Xeros' model is to generate revenue from
licensing its technologies, generating royalties and the sale of
consumables. Currently there are 8 agreements in place. The
addressable markets in Filtration, Finish and Care are estimated to
be valued at £350m p.a., £132m p.a. and £3bn p.a.
respectively.
Chairman's Statement
Given my detailed letter to shareholders in the
Circular dated 8 April 2024, I will keep this year's statement
brief, concentrating on what is new, important and different.
Under the impressive leadership of Neil Austin, the
Group has transitioned from an engineering led organisation to a
sales-led organisation. The Group welcomed five, highly capable
employees into new, commercial roles during the year, generating a
pipeline of 10 new opportunities. The Group is now in direct
dialogue with six of the 10 leading global domestic washing machine
manufacturers for its Care and Filtration technologies. While these
may not all come to fruition, the quantum and quality of interest
being generated by our new commercial team is extremely
encouraging.
We have completed the technology transfer process
with IFB (Care technology) and Yilmak Makina (Finishing
technology). The completion of these processes is a key milestone
with both partners as it now enables the commercial roll-out of
machines equipped with Xeros IP. Further information on the
tangible progress being made on these and our other licensing
agreements is given in the CEO's report.
The team has achieved all of this, while maintaining
tight control of costs and a keen focus on achieving breakeven.
The Group's balance sheet has been significantly
strengthened by a post year-end warrant exercise and fundraise,
providing the Group with additional working capital of £6.3m before
fees to support the delivery of our FY24 and FY25 goals.
The Board underwent significant change in 2022 upon
which the Nominations Committee has reviewed the structure and
skill set of the current Board. It has concluded that, with the
appointment of Alex Tristram as Finance Director in April 2024, it
meets the current needs of the Group. The Committee will continue
to monitor the suitability of the Board's composition, as the
Company completes its transition to a full-fledged commercial
enterprise.
As always, I want to thank you, shareholders, for
your continued support of the business (through both the warrant
exercise and participation in the recent financing), but also want
to express my gratitude to our management team, all staff,
commercial partners and my board colleagues for all your continued
dedication to our cause: the adoption at scale of Xeros' extremely
compelling and necessary technologies.
While we remain dependent on commercial delivery by
licensees, the route to meaningful revenue is becoming clearer.
With IFB and Yilmak Makina in final preparation for commercial
scale roll-out later this year, we believe we are closer than ever
to that inflection point.
Klaas de Boer
Chairman
28 May 2024
CEO Statement
I am pleased to report that the Group made
significant operational and commercial progress in the year to 31
December 2023, with further significant milestones being achieved
post year end.
Our agreements with licensees moved closer to
commercial launch, as we embarked on the crucial technology
transfer process with both IFB and Yilmak Makina. We completed the
technology transfer for IFB domestic machines (Goa) in December
2023, and Yilmak Makina's commercial denim processing machines
(Turkey) in Q1 of the new financial year. All these machines have
now moved to the manufacture and marketing stage, ahead of scale
launch. This gives the Board confidence that the Group remains on
track to achieve month-on-month operational breakeven.
In addition, the work undertaken to increase
the Group's commercial focus has resulted in a stronger than
expected pipeline of potential new agreements. We are now in
discussion with 10 major organisations with interest across all the
Group's technologies.
This progress, supported by the funds raised
post period-end of £6.3m before fees, puts the Group in a strong
position to execute its commercialisation strategy on existing
opportunities, whilst also generating new ones.
The macro environment for our technologies
continues to strengthen, in synchrony with our commercialisation
goals. Global businesses are coming under increasing pressure to
improve their environmental practices. Governments are introducing
new regulations and legislation to protect against further
ecological damage and meet their global obligations. Xeros
continues to be called upon to provide expert testimony on
microfibre capture to feed into legislative initiatives in the
U.S., European Union and the UK.
Operational
review and progress
When I joined Xeros in August 2022, I talked
about targeting change, which I have done in three parts. During my
first six months, I reviewed the business proposition, the pipeline
of opportunity for commercialisation, and the people. That
initial period of evaluation told me that, on all three of our
technology platforms, our proposition was incredibly
compelling. After some 20 years of commercial experience, I
recognised an extremely rare opportunity to offer both
environmental solutions alongside improved efficiency and cost
savings for two huge global industries, apparel manufacture and
laundry. These industries had not innovated in decades and were
slow to adopt better environmental practices, although under
significant pressure to do so.
When canvassing the opinion of key industry
players on Xeros' Care, Finish and Filtration technologies, the
feedback was unanimous and clear. The combination of our authentic
desire to help the planet and ability to reduce, not increase,
their input costs to achieve a positive outcome is a compelling
proposition.
The second part of the change was to accelerate
the commercialisation process. Before I joined Xeros, the Group had
courted some significant players in the industry but had not
managed to achieve any meaningful commercial traction.
Investors often asked me why this was the case. I believe it
resulted from a well-meaning attempt to 'launch' the technology
before it was really market ready, and then, following the
strategic change to the current licensing model, progress was
hindered by the turbulent socio-economic issues triggered by the
Pandemic.
Since putting in place a new operational
framework and improved processes, our extremely capable team of
engineers and scientists has flourished. A new contract was signed
in April 2023 with Yilmak Makina and, after what has been a lengthy
period of education for our industry licensees, some of the Group's
contracts with IFB are now nearing market launch having completed
the technical transfer process.
People
Perhaps the most important element I have
reshaped has been people.
I have mentioned on several occasions that the
people in Xeros, our scientists and engineers, are amongst the
brightest, most passionate and intelligent that I have had the
fortune to lead. I am reminded of this on a daily basis. What the
team lacked, however, was commercial acumen, and a 'pace and
rhythm' of activity necessary for commercialisation. Any successful
business is characterised by a high performing, driven sales and
marketing effort. I am delighted that during 2023, we
reinforced our team with industry expertise and a sales programme
full of ambition and confidence. We have added five new roles,
incorporating further expertise in category marketing, licensing
sales and applicable business knowledge from the white goods and
denim processing industries. The success of this team is evidenced
by the full sales pipeline described below.
As well as bringing a new operational
'commerciality' led by sales and marketing, I was keen to surround
the business with experience, know-how and sage advice. This has
been achieved through the creation of an Advisory Board, consisting
of high-quality individuals with a lifetime of experience in some
of the world's largest organisations. People who are passionate
about Xeros' technology. Being able to call upon the highest level
of engineering, sales, science, retail, and marketing capability
has been a key enabler for the Group in 2023 and we expect further
benefits on future projects.
Business
update
Filtration
(XF1 - domestic, XF2 -
commercial, XF3 - external)
We have made significant progress in
Filtration, adding two licensing agreements with major European
component manufacturers for XF1 in H1 2023. We now have three
agreements in place, which equate to an 'approved supplier'
coverage for 99% of the 105 million washing machines produced
annually.
In September 2023 at IFA Berlin, Europe's
largest consumer electronics show, we launched a new external
filtration product for the domestic market, the XF3. This is an
'outside-of-machine' microplastic filtration device, which can be
retrofitted to the existing domestic install base with full
flexibility of placement. The XF3 has all the features of XF1, a
market leading microfibre capture rate of 99% with no requirement
for replacement cartridges and is lifetime of machine tested.
Interest at IFA was overwhelming, and we are currently in
negotiations to manufacture and distribute the XF3 under licence.
The aim is for a full market launch later this year.
Finish (XFN1 - Denim and XFN2 -
Washing)
Having signed an agreement in April 2023 with
Yilmak Makina / KRM, one of the world's largest and best respected
garment finishing manufacturers and distributors respectively, they
previewed their new Xeros-enabled denim processing machine at ITMA
in Milan, the world's most influential textile and garment
technology exhibition. For Yilmak Makina, it was the first
manifestation of the licence, and the feedback was excellent with
several soft orders taken on the stand. Post the year end, in
February 2024, Yilmak Makina concluded the technical transfer of
fitting an XDrum and XOrb capability to their core machine. This
important milestone was achieved some three months ahead of
schedule and precedes a full marketing launch of the machine at the
ITM trade show, one of the most important meeting points in the
field of textile machinery in Istanbul in June 2024.
Our existing licensing agreement with Ramsons,
a leading full range supplier of equipment solutions to the apparel
industry in South and East Asia, which was signed in March 2020 for
denim finishing in India, continues to make progress with new
installations expected at one of Sri Lanka's largest garment
manufacturers in 2024.
We have also seen some important progression on
the 'demand' side of the industry, with retail brands keen to
promote more environmentally friendly/conscious fashion. As shown
by a leading garment brand and a European retail chain being in the
process of specifying Xeros' technology in the recipe of their core
denim ranges.
Care (XC1 - domestic and XC2 -
commercial)
As outlined above, an important milestone in
the agreement with IFB was achieved in the Period. IFB and Xeros
engineers concluded the technical transfer process on a mass market
9kg domestic washing machine in December. I am pleased to report
that subsequent field trials have been successful, and the project
has now moved from R&D into manufacturing and marketing. IFB is
targeting a launch later this calendar year.
Our long-standing partner in France, Georges, a
leading commercial laundry business that specialises in the
cleaning and maintenance of workwear and PPE, continues to thrive
using Xeros-enabled IFB machines with plans to open new sites over
the next 12-18 months, in line with their expansion into the
laundering of fire fighter uniforms. In addition, Georges has
received compelling feedback from its key customer base, Air France
and SNCF, with statistics showing a uniform life extension of 20%
since using the Xeros CARE technology.
In addition, early in the Period, we appointed
Ecoprod as a UK distributor for Xeros enabled commercial care
machines. The UK based company offers water management solutions to
several thousand facilities in five major industries - healthcare,
hotels, the care market, laundry companies and sports
clubs.
Sales
pipeline
The Company's goal is mass implementation of
its three technologies and, to this aim, I come to my third element
of change, which is now well underway. Fueled by the confidence of
our progress with licensees, we led a programme of outreach to
global players with a goal for 2023 to gain interest from a major
European washing machine brand on each of our three technology
platforms. As I write today, we are trending significantly beyond
that initial target, and I am pleased to report that we are now in
dialogue with six out of the 10 leading global domestic washing
machine manufacturing brands and have 10 new commercial
opportunities including those referenced above:
For
Filtration (domestic)
|
·
|
four global brands
|
|
|
For
Finish
|
·
|
a leading global fashion brand
|
·
|
a major European retailer
|
|
|
For Care
(commercial)
|
·
|
two global brands
|
|
|
For Care
(domestic)
|
·
|
two European brands
|
·
|
a North American brand
|
·
|
an Asian brand
|
While we would not expect all of these to come
to fruition, the response we have had is extremely
encouraging.
Strategy
Our strategy to become an IP-rich,
capital-light licensor of proprietary technology solutions to
multiple scale industries, all of which deploy the same Xeros core
technologies remains.
Our technology provides cost-effective
solutions for garment manufacture and clothing care within the $2.5
trillion fashion industry and the $55 billion domestic washing
machine market. Our annual addressable markets in Filtration,
Finish and Care are estimated to be £350 million, £132 million and
£3 billion respectively.
To achieve market penetration, we take a
three-pronged approach:
·
|
Commercial
partnerships - We have commercial partnerships in
place with IFB for domestic and commercial laundry machines, with
Ramsons and Yilmak/KRM for garment finishing equipment, and with
three component manufacturers on XF1.
|
·
|
Direct
engagement - We engage and work to influence major fashion
and consumer brands to showcase the benefits of our technology and
to build a market for it. We have significant engagement with
leading global OEMs across all our technology platforms.
|
·
|
Drive
influence - We are a global leader in sustainable textile
technologies and we work with legislators, industry groups and NGOs
to show the scale of the environmental challenges and to
demonstrate the effectiveness of our solutions.
|
ESG
Xeros' technologies reduce the environmental
impact of clothing on the planet. They save millions of litres of
water and have the power to prevent billions of microfibres ending
up in our oceans.
Textiles technologies are just the beginning of
our long-term mission to reduce waste and use resources more
responsibly to support a better future for both people, and the
world we call our home.
We are pleased to have been recognised as a B
Corp business during the Period. We are part of a global movement
of companies dedicated to using business as a force for good. We
are proud to be included in a network of over 6,000 mission-led
businesses, committed to meeting the rising standards for social
and environmental performance.
Post Period
End and Outlook
As detailed in the circular for the fundraise,
dated 8 April, the Board conservatively estimates Xeros' core
technologies provide an addressable global market opportunity of
c£40m-£50m pa in revenue in the medium term.
The £6.3m before fees funds raised from the
placing and retail offer in April 2024, and the warrant redemptions
received in January 2024 will be used to strengthen the balance
sheet and provide working capital to support our existing partners
through to launch (IFB, Yilmak Makina and Ecoprod); the progression
of the significant global opportunities referenced above; provide
contingency against timing of royalty payments, over which we have
little control; and for developing complementary additions to our
core propositions not least on filtration.
Cost controls will remain in place, and
priority will be given to the commercialisation of existing
opportunities.
As a technology licensing business, we have the
benefits of low overheads, a high margin business model and an
ability to scale up significantly with minimal cost increase.
The other side of the coin however is that we are unable to
directly influence timings and 'Go to Market' decisions.
Nonetheless, the route to nearer-term meaningful revenue is clear,
with a number of our commercial partners, as detailed above, now
close to commercial scale roll-out of machinery containing some
element of Xeros' IP.
Neil
Austin
Chief Executive Officer
28 May 2024
Financial
review
Group revenue was generated as
follows:
|
Year
ended
|
Year
ended
|
|
31 December
|
31
December
|
|
2023
|
2022
|
|
£'000
|
£'000
|
|
|
|
Service revenue
|
82
|
82
|
Licensing revenue
|
138
|
64
|
Sale of goods
Other
|
77
-
|
18
-
|
|
_______
|
_______
|
Total revenue
|
297
|
164
|
|
|
|
|
|
|
The financial results in 2023 show development
of the Group's licencing strategy alongside management of costs in
order the put the Group into a strong position, and while revenue
growth in FY23 was not as strong as anticipated due to the timing
of XOrb orders from partners, it does support the anticipated
revenue growth as contracts enter into their commercial
phase.
The Group's future revenue is based upon the
anticipated commercial progress made by its commercial partners as
they market and sell products incorporating Xeros technology into
their respective markets. The Group has worked to set a cost base
which can support these contracts as well as win new ones, with the
expectation that costs will not need to rise significantly in
future years as the Group moves into profitability.
Further information on these financial results
is provided below.
Group revenue increased by 81.1% to £0.30m in
the year ended 31 December 2023 (2022: £0.16m). The Group's revenue
is derived from three principal sources:
·
|
Service revenue: reflecting the servicing of
existing estate, based principally in Europe.
|
·
|
Licensing revenue: reflecting royalty payments
from licence partners, milestone payments during the technology
transfer process and advance fees for access to Group intellectual
property.
|
·
|
Sale of goods: reflecting sales of XOrbs to
licence partners and sales of machines on behalf of licence
partners.
|
The Group continues to receive service revenue
related to the retained estate of commercial laundry machines in
the UK and Europe. As the licensing model grows, this service
revenue is expected to become a smaller part of the overall revenue
mix.
Licensing revenue in the period was £0.14m
(2022: £0.06m), an increase of 115.6%; revenue from sale of goods
was £0.08m in the period (2022: £0.02m), an increase of 377.8%.
Service revenue in the period was flat at £0.08m (2022:
£0.08m).
The increase in revenue and the high margins
the Group records on licence income has driven an increase in gross
profit in the period to £0.25m (2022: £0.08m), an increase of
81.1%, resulting in a gross margin of 82.5% (2022:
51.2%).
The Group decreased its adjusted EBITDA loss by
37.5% to £4.6m (2022: loss £7.4m).
Gross profit/loss and adjusted EBITDA are
considered the key financial performance measures of the Group as
they reflect the trading activities of the Group. Adjusted EBITDA
is defined as the loss on ordinary activities before interest, tax,
share-based payments and warrant expense, depreciation and
amortisation.
Administrative expenses, decreased by 33.7% to
£5.0m (2022: £7.5m), following a reduction in the Group's headcount
and a continued focus on cost across the business. The Group's
average headcount fell by 26.8% in the year to 30 (2022:
41).
The Group reported an operating loss of £4.7m
(2022: loss £7.4m), a decrease of 33.2%. The loss per share was
2.82p (2022: loss 14.29p).
Net cash outflow from operations decreased by
33.2% to £4.7m (2022: £7.0m) as a result of the Group's overall
cost reduction, as shown in a reduction in cash used in operations
to £5.2m (2022: £7.5m), and the receipt of £0.5m R&D tax
credits from HMRC relating to 2022. Cash utilisation was in line
with the Board's expectations. Cash utilisation is not expected to
increase during 2024.
The Group had existing cash resources,
including cash on deposit, as at 31 December 2023 of £1.6m (2022:
£6.5m) and remains debt free. The Group received additional funding
post period end in the form of warrant exercises and an equity
placing, which between them raised £6.3m before fees. The Going
Concern statement within this announcement draws attention to the
Directors' views on the Group's ongoing prospects and the key
assumptions behind the preparation of the Group's Annual Report for
the year ended 31 December 2023 on a going concern
basis.
Alex Tristram
Finance Director
28 May 2024
Consolidated
statement of profit or loss and other comprehensive
income
For the year ended 31 December 2023
|
|
Year
|
Year
|
|
|
ended
|
ended
|
|
|
31
December
|
31
December
|
|
|
2023
|
2022
|
|
Notes
|
£'000
|
£'000
|
Continuing operations
|
|
|
|
REVENUE
|
|
297
|
164
|
Cost of sales
|
|
(52)
|
(80)
|
GROSS PROFIT/(LOSS)
|
|
245
|
84
|
|
|
|
|
Administrative expenses
|
|
(4,982)
|
(7,518)
|
|
|
|
|
Adjusted EBITDA*
|
|
(4,606)
|
(7,368)
|
Share-based payment
credit/(expense)
|
|
20
|
79
|
Depreciation of tangible fixed
assets
|
|
(151)
|
(145)
|
|
|
|
|
OPERATING LOSS
|
|
(4,737)
|
(7,434)
|
Net finance
(expense)/income
|
|
(38)
|
(14)
|
LOSS BEFORE TAX
|
|
(4,775)
|
(7,448)
|
Taxation
|
|
520
|
515
|
LOSS FOR THE PERIOD
|
|
(4,255)
|
(6,933)
|
|
|
|
|
OTHER COMPREHENSIVE (EXPENSE)/INCOME:
|
|
|
|
Items that are or may be reclassified to profit or
loss:
|
|
|
|
Foreign currency translation
differences - foreign operations
|
|
2,209
|
(3)
|
TOTAL COMPREHENSIVE EXPENSE FOR THE PERIOD
|
|
(2,046)
|
(6,936)
|
|
|
|
|
LOSS PER SHARE
|
|
|
|
Basic and diluted on loss from continuing
operations
|
|
(2.82)p
|
(14.29)p
|
Basic and diluted on total loss for the
period
|
|
(2.82)p
|
(14.29)p
|
* Adjusted EBITDA comprises loss on ordinary
activities before interest, tax, share-based payment expense,
warrant expense, depreciation and amortisation.
Consolidated
statement of changes in equity
For the year ended 31 December 2023
|
Share
capital
|
Share
premium
|
Deferred share
capital
|
Warrant
reserve
|
Merger
reserve
|
Foreign currency translation
reserve
|
Accumulated
losses
|
Total
|
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
|
|
|
|
|
|
|
|
|
Balance at 31 December 2021
|
3,568
|
121,018
|
-
|
-
|
15,443
|
(2,206)
|
(130,761)
|
7,062
|
Loss for the year
|
-
|
-
|
-
|
-
|
-
|
-
|
(6,933)
|
(6,933)
|
Other comprehensive
income
|
|
|
|
|
|
(3)
|
-
|
(3)
|
Loss and total comprehensive expense
for the period
|
-
|
-
|
-
|
-
|
-
|
(3)
|
(6,933)
|
(6,936)
|
Transactions with owners, recorded
directly in equity:
|
|
|
|
|
|
|
|
|
Change in nominal value of ordinary
shares
|
(3,544)
|
-
|
3,544
|
-
|
-
|
-
|
-
|
-
|
Issue of shares following placing
and open offer
|
127
|
6,234
|
-
|
-
|
-
|
-
|
-
|
6,361
|
Costs of share issues
|
-
|
(539)
|
-
|
-
|
-
|
-
|
-
|
(539)
|
Warrant expense
(restated)
|
-
|
(947)
|
-
|
947
|
-
|
-
|
-
|
-
|
Share-based payment
Expense
|
-
|
-
|
-
|
-
|
-
|
-
|
(79)
|
(79)
|
Total contributions by and
distributions to owners (restated)
|
(3,417)
|
4,748
|
3,544
|
947
|
-
|
-
|
(79)
|
5,743
|
At
31 December 2022 (restated)
|
151
|
125,766
|
3,544
|
947
|
15,443
|
(2,209)
|
(137,773)
|
5,869
|
Loss for the year
|
-
|
-
|
-
|
-
|
-
|
-
|
(4,255)
|
(4,255)
|
Other comprehensive
expense
|
-
|
-
|
-
|
-
|
-
|
10
|
-
|
10
|
Other comprehensive expense:
Reclassification of historical foreign exchange on the closure of
overseas subsidiaries
|
-
|
-
|
-
|
-
|
-
|
2,199
|
(2,199)
|
-
|
Loss and total
comprehensive
expense for the
year
|
-
|
-
|
-
|
-
|
-
|
2,209
|
(6,454)
|
(4,245)
|
Transactions with owners,
recorded directly in
equity:
|
|
|
|
|
|
|
|
|
Share-based payment
Expense
|
-
|
-
|
-
|
-
|
-
|
-
|
(20)
|
(20)
|
Total contributions by
and
distributions to
owners
|
-
|
-
|
-
|
-
|
-
|
-
|
(20)
|
(20)
|
At
31 December 2023
|
151
|
125,766
|
3,544
|
947
|
15,443
|
-
|
(144,247)
|
1,604
|
|
|
|
|
|
|
|
|
| |
Consolidated
statement of financial position
As at 31 December 2023
|
|
At
|
Restated
At
|
|
|
31
December
|
31
December
|
|
|
2023
|
2022
|
|
Notes
|
£'000
|
£'000
|
ASSETS
|
|
|
|
Non-current assets
|
|
|
|
Property, plant and
equipment
|
|
129
|
104
|
Right of use assets
|
|
772
|
717
|
Trade and other
receivables
|
|
-
|
6
|
TOTAL NON-CURRENT ASSETS
|
|
901
|
827
|
Current assets
|
|
|
|
Inventories
|
|
159
|
164
|
Trade and other
receivables
|
|
352
|
387
|
Cash on deposit
|
|
4
|
4
|
Cash and cash equivalents
|
|
1,595
|
6,465
|
TOTAL CURRENT ASSETS
|
|
2,110
|
7,020
|
TOTAL ASSETS
|
|
3,011
|
7,847
|
LIABILITIES
|
|
|
|
Non-current liabilities
|
|
|
|
Right-of-use liabilities
|
|
(727)
|
(624)
|
Deferred tax
|
|
(38)
|
(38)
|
TOTAL NON-CURRENT LIABILITIES
|
|
(765)
|
(662)
|
Current liabilities
|
|
|
|
Trade and other payables
|
|
(642)
|
(1,316)
|
TOTAL CURRENT LIABILITIES
|
|
(642)
|
(1,316)
|
TOTAL LIABILITIES
|
|
(1,407)
|
(1,978)
|
NET
ASSETS
|
|
1,604
|
5,869
|
EQUITY
|
|
|
|
Share capital
|
|
151
|
151
|
Share premium
|
|
125,766
|
125,766
|
Deferred share capital
|
|
3,544
|
3,544
|
Warrant reserve
|
|
947
|
947
|
Merger reserve
|
|
15,443
|
15,443
|
Foreign currency translation
reserve
|
|
-
|
(2,209)
|
Accumulated losses
|
|
(144,247)
|
(137,773)
|
TOTAL EQUITY
|
|
1,604
|
5,869
|
Consolidated
statement of cash flows
For the year ended 31 December 2023
|
|
Year
|
Year
|
|
|
ended
|
ended
|
|
|
31 December
|
31
December
|
|
|
2023
|
2022
|
|
Notes
|
£'000
|
£'000
|
Operating
activities
|
|
|
|
Loss before
tax
|
|
(4,775)
|
(7,448)
|
Adjustment
for non-cash items:
|
|
|
|
Depreciation of property, plant and equipment
|
|
151
|
145
|
Share-based
payment
|
|
(20)
|
(79)
|
(Decrease)/Increase in inventories
|
|
5
|
(56)
|
(Increase)/decrease in trade and other receivables
|
|
40
|
(15)
|
Decrease in
trade and other payables
|
|
(615)
|
(46)
|
Finance
income
|
|
(2)
|
(16)
|
Finance
expense
|
|
39
|
30
|
Cash used in
operations
|
|
(5,177)
|
(7,485)
|
Tax
receipts
|
|
520
|
515
|
Net cash outflow from
operations
|
|
(4,657)
|
(6,970)
|
|
|
|
|
INVESTING
ACTIVITIES
|
|
|
|
Purchases
of property, plant and equipment
|
|
(79)
|
(63)
|
Cash
removed/(placed on) deposit
|
|
-
|
5,319
|
Net cash inflow/(outflow)
from investing activities
|
|
(79)
|
5,256
|
|
|
|
|
FINANCING
ACTIVITIES
|
|
|
|
Finance
income
|
|
1
|
15
|
Finance
expense
|
|
(39)
|
(30)
|
Proceeds
from issue of share capital, net of costs
|
|
-
|
5,821
|
Payment of
lease liabilities
|
|
(105)
|
(113)
|
Net cash inflow from
financing activities
|
|
(143)
|
5,693
|
|
|
|
|
Increase/(decrease) in cash and cash equivalents
|
|
(4,879)
|
3,979
|
Cash and
cash equivalents at start of year/period
|
|
6,469
|
2,483
|
Effect of
exchange rate fluctuations on cash held
|
|
7
|
3
|
CASH AND CASH EQUIVALENTS AT
END OF YEAR
|
|
1,597
|
6,465
|
Notes to the
consolidated financial statements
For the year ended 31 December 2023
1) BASIS OF
PREPARATION
The financial information has been
prepared in accordance with the recognition and measurement
principles of International Accounting Standards in conformity with
the requirements of the Companies Act 2006 and in accordance with
the AIM rules. The principal accounting policies of the Group have
remained unchanged from those set out in the Group's 2022 annual
report.
The financial information has been
prepared under the historical cost convention and is presented in
Sterling, rounded to the nearest thousand.
The financial information set out in
this preliminary announcement does not constitute statutory
accounts as defined by section 434 of the Companies Act 2006. The
financial information for the period ended 31 December 2023 was
approved by the Board on 24 May 2024 and has been extracted from
the Group's financial statements upon which the auditor's opinion
is unmodified and does not include a statement under section 498(2)
or (3) of the Companies Act 2006, but does include an emphasis of
matter regarding the material uncertainty related to going concern
described below.
The statutory accounts for the
period ended 31 December 2023 will be posted to shareholders at
least 21 days before the Annual General Meeting and made available
on our website www.xerostech.com.
In due course, they will be delivered to the Registrar of
Companies. The statutory accounts for the period ended 31 December
2022 have been delivered to the Registrar of Companies.
The preparation of financial
statements in conformity with UK-adopted International Accounting
Standards requires management to make judgements, estimates and
assumptions that affect the application of policies and reported
amounts of assets and liabilities, income, and expenses. The
estimates and associated assumptions are based on historical
experience and various other factors that are believed to be
reasonable under the circumstances, the results of which form the
basis of making the judgements about carrying values of assets and
liabilities that are not readily apparent from other sources.
Actual results may differ from these estimates.
The estimates and underlying
assumptions are reviewed on an ongoing basis. Revisions to
accounting estimates are recognised in the period in which the
estimate is revised if the revision affects only that period, or in
the period of the revision and future periods if the revision
affects both current and future periods.
In preparing the financial
information, management are required to make accounting assumptions
and estimates. The assumptions and estimation methods are
consistent with those applied to the annual report and financial
statements for the year ended 31 December 2022. Additionally, the
principal risks and uncertainties that may have a material impact
on activities and results of the Group remain materially unchanged
from those described in that annual report.
Business combinations and basis of
consolidation
Subsidiaries are all entities
(including structured entities) over which the Group has control.
The Group controls an entity when the Group is exposed to, or has
rights to, variable returns from its involvement with the entity
and has the ability to affect those returns through its power over
the entity. Subsidiaries are fully consolidated from the date on
which control is transferred to the Group and are deconsolidated
from the date control ceases.
Inter-company transactions, balances
and unrealised gains and losses on transactions between Group
companies are eliminated.
Where the acquisition is treated as
a business combination, the purchase method of accounting is used
to account for the acquisition of subsidiaries by the
Group.
The cost of an acquisition is
measured as the fair value of the assets given, equity instruments
issued and liabilities incurred or assumed at the date of
exchange. Acquisition costs are expensed as incurred.
Identifiable assets acquired and liabilities and contingent
liabilities assumed in a business combination are measured
initially at their fair values at the acquisition date. The
excess of the cost of acquisition over the fair value of the
Group's share of the identifiable net assets acquired is recorded
as goodwill. If the cost of the acquisition is less than the
fair value of net assets of the subsidiary acquired, the difference
is recognised directly in the income statement.
All intra-group balances and
transactions, including unrealised profits arising from intra-group
transactions, are eliminated fully on consolidation.
Going
Concern
As at 31 December 2023, the Group had £1.6m of
cash and cash equivalents. At this stage of its development, the
Group incurs operating cash outflows and is reliant on existing
cash resources. The Group's received £1.7m of cash in respect of
warrant exercises during January 2024, and during April 2024, the
Group completed an equity placing and retail offer which provided
an additional £4.6m before fees. The Directors consider that,
following these, the Group has sufficient cash to meet its
obligations as they fall due for at least 12 months following the
date of this announcement. The Directors also believe that these
financial resources, alongside the Group's existing and anticipated
customer contracts, provide the Group with a platform to reach cash
breakeven.
While the Group actively manages key customer
stakeholders where appropriate, the revenue anticipated to allow
the Group to reach cash breakeven anticipated to be generated by
these contracts is reliant on the actions of third parties and
there remains risk that progress is not forthcoming in the
timeframes anticipated by the Directors. Should there be
significant delays in the commencement of the commercialisation of
the Group's technology by its licence partners, the Group's
existing cash balance may not be sufficient to support the Group's
expenditure until the point the Group's revenue allows it to reach
cash breakeven.
The Directors consider that they have a number
of options in place should there be delays in commercialisation,
including reductions in discretionary spending, that would allow
the existing cash resources to provide a longer runway. Given the
lack of certainty around the timing of the commencement of
significant revenues generated by the Group, the Directors consider
that the Group's current funding position constitutes a material
uncertainty that may cast significant doubt as to the Group's
ability to continue as a going concern; in the absence of
significant customer revenue, the Group's cash will run out.
Notwithstanding this uncertainty, the Directors believe that they
have sufficient options in place in order to allow the Group to
continue trading in the short and medium term. Therefore, after
making enquiries and considering the uncertainties as described
above, the Directors have a reasonable expectation that the Group
has and will have adequate resources to continue in operational
existence for the foreseeable future. For these reasons, they
continue to adopt the going concern basis of accounting in
preparing this financial information.
The Group is subject to a number of risks,
including those as set out in the strategic report within the
Group's Annual Report. These risks include the global
macro-economic conditions, particularly in the global markets in
which the Group and its partners operate. The going concern
assessment as carried out by the Directors has taken the impact of
these into account as far as possible. While this inclusion does
not change the assessment of the Directors in respect of going
concern, the Group remains reliant on the progress of international
licence partners in order for it to execute the commercialisation
strategy.
When making their going concern assessment the
Directors assess available and committed funds against all
non-discretionary expenditure, and related cash flows, as forecast
for the period ended 31 December 2025. These forecasts indicate
that the Group is able to settle its liabilities as they fall due
in the forecast period. In these forecasts the Directors have
considered appropriate sensitivities, including the progress of the
Group's commercial contracts. Accordingly, the Directors continue
to believe that the going concern assumption is appropriate for the
Group and the financial statements have been prepared on that
basis.
2) SEGMENTAL
REPORTING
The financial information by segment detailed
below is frequently reviewed by the Chief Executive Officer, who
has been identified as the Chief Operating Decision Maker ("CODM").
The Group's transition to a licensing organisation has led to a
change to how the results of the Group are reviewed internally. The
results are no longer split by segment but are reviewed in terms of
the type of revenue. As such, the analysis below does not split the
Group's results into separate operating segments and instead
reports results as one single segment.
An analysis of revenues by type is set out
below:
|
Year
|
Year
|
ended
|
ended
|
31 December
|
31
December
|
2023
|
2022
|
|
£'000
|
£'000
|
Sale of goods
|
77
|
18
|
Rendering of services
|
82
|
82
|
Licensing revenue
|
138
|
64
|
|
297
|
164
|
The Group's largest customer was responsible
for 32% of Group revenue in the year to 31 December
2023.
During the year ended 31 December 2022 the
Group's largest customer was responsible for 31% of Group
revenue.
An analysis of revenues by geographic location
of customers is set out below:
|
Year
|
Year
|
ended
|
ended
|
31 December
|
31
December
|
2023
|
2022
|
|
£'000
|
£'000
|
Europe
|
161
|
120
|
North America
|
8
|
31
|
Rest of the World
|
128
|
13
|
|
297
|
164
|
3) LOSS
FROM OPERATIONS
|
Year
|
Year
|
ended
|
ended
|
|
31 December
|
31
December
|
|
2023
|
2022
|
|
£'000
|
£'000
|
Loss from operations is stated after
charging to
administrative expenses:
|
|
|
Foreign exchange
losses
|
3
|
16
|
Depreciation of plant
and
equipment
|
151
|
145
|
Short term and low
value rentals
|
16
|
42
|
Staff costs (excluding
share-based payment charge)
|
2,661
|
4,009
|
Research and
development
|
222
|
837
|
|
|
|
Auditors remuneration:
|
|
|
- Audit of these financial
statements
|
24
|
38
|
- Audit of financial statements of
subsidiaries of the company
|
23
|
30
|
·
- Audit related assurance services
|
4
|
5
|
Total auditor's
remuneration
|
51
|
73
|
4) EXPENSES BY
NATURE
The administrative expenses charge by nature is
as follows:
|
Year
|
Year
|
Ended
|
ended
|
31 December
|
31
December
|
2023
|
2022
|
|
£'000
|
£'000
|
Staff costs, recruitment and other
HR
|
2,735
|
4,221
|
Share-based payment
(credit)/expense
|
(20)
|
(79)
|
Premises and establishment
costs
|
160
|
157
|
Research and development
costs
|
84
|
259
|
Patent and IP costs
|
549
|
687
|
Legal, professional and consultancy
fees
|
617
|
1,088
|
IT, telecoms and office
costs
|
164
|
265
|
Depreciation charge
|
151
|
145
|
Travelling, subsistence and
entertaining
|
275
|
329
|
Advertising, conferences and
exhibitions
|
256
|
360
|
Bad debt expense
|
10
|
64
|
Other expenses
|
(2)
|
6
|
Foreign exchange
losses/(gains)
|
3
|
16
|
|
|
|
Total administrative expenses
|
4,982
|
7,518
|
5)
TAXATION
Tax on loss on
ordinary activities
|
Year
|
Year
|
ended
|
ended
|
|
31 December
|
31
December
|
|
2023
|
2022
|
|
£'000
|
£'000
|
Current tax:
|
|
|
UK Tax credits received in respect
of prior periods
|
(521)
|
(517)
|
Foreign taxes paid
|
1
|
2
|
|
(520)
|
(515)
|
Deferred tax:
|
|
|
Origination and reversal of
temporary timing differences
|
-
|
-
|
Tax
credit on loss on ordinary activities
|
(520)
|
(515)
|
The credit for the year can be reconciled to
the loss before tax per the statement of profit or loss and other
comprehensive income as follows:
Factors
affecting the current tax charges
The tax assessed for the year varies from the
main company rate of corporation tax as explained below:
|
Year
|
Year
|
ended
|
ended
|
|
31 December
|
31
December
|
|
2023
|
2022
|
|
£'000
|
£'000
|
The tax assessed for the period
varies from the main company rate of corporation tax as explained
below:
|
|
|
Loss on ordinary activities before
tax
|
(4,775)
|
(7,448)
|
|
|
|
Tax at the standard rate of
corporation tax 19% (2022: 19%)
|
(907)
|
(1,415)
|
|
|
|
Effects of:
|
|
|
Expenses not deductible for tax
purposes
|
(4)
|
(15)
|
Research and development tax credits
receivable
|
(521)
|
(517)
|
Unutilised tax losses for which no
deferred tax asset is
recognised
|
911
|
1,430
|
Employee share acquisition
adjustment
|
-
|
-
|
Foreign taxes paid
|
1
|
2
|
Tax
credit for the year
|
(520)
|
(515)
|
The Group accounts for Research and Development
tax credits where there is certainty regarding HMRC approval. The
Group has received a tax credit in respect of the year ended 31
December 2022. There is no certainty regarding the claim for the
year ended 31 December 2023 and as such no relevant credit or asset
is recognised.
6) LOSS PER
SHARE (BASIC AND DILUTED)
Basic loss per share is calculated by dividing
the loss attributable to equity holders of the parent by the
weighted average number of ordinary shares in issue during the
year. Diluted loss per share is calculated by adjusting the
weighted average number of ordinary shares in issue during the
period to assume conversion of all dilutive potential ordinary
shares.
|
Year
|
Year
|
|
ended
|
ended
|
|
31 December
|
31
December
|
|
2023
|
2022
|
|
£'000
|
£'000
|
Total loss from continuing operations
|
(4,255)
|
(6,933)
|
|
|
|
Total loss attributable to the equity holders of the
parent
|
(4,255)
|
(6,933)
|
|
|
|
|
No.
|
No.
|
Weighted average number of ordinary shares in issue during the
year
|
150,982,728
|
48,526,649
|
|
|
|
Loss per share
|
|
|
Basic and diluted on loss from
continuing operations
|
(2.82)p
|
(14.29)p
|
|
|
|
Basic and diluted on total loss for
the year
|
(2.82)p
|
(14.29)p
|
The weighted average number of shares in issue
throughout the period is as follows.
|
Year
|
Year
|
|
ended
|
ended
|
|
31 December
|
31
December
|
|
2023
|
2022
|
Issued ordinary shares at 1 January
2023/1 January 2022
|
150,980,123
|
23,784,483
|
Effect of shares issued for
cash
|
2,605
|
24,742,166
|
Weighted average number of shares at
31 December
|
150,982,728
|
48,526,649
|
The Company has issued employee options over
9,557,130 (31 December 2022: 10,852,514) ordinary shares which are
potentially dilutive. There is, however, no dilutive effect of
these issued options as there is a loss for each of the periods
concerned.
7) SHARE
CAPITAL AND WARRANTS
|
|
Share
capital
|
Share
premium
|
Deferred share
capital
|
Merger
reserve
|
Total
|
|
Number
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
Total ordinary shares of 15p each as at 31 December
2021
|
23,784,483
|
3,568
|
121,018
|
-
|
15,443
|
140,029
|
Change in nominal value of ordinary
shares
|
-
|
(3,544)
|
-
|
3,544
|
-
|
-
|
Issue of ordinary shares following
placing and open offer
|
127,195,640
|
127
|
6,234
|
-
|
-
|
6,361
|
Costs of share issues
|
-
|
-
|
(539)
|
|
-
|
(539)
|
Warrant expense
|
-
|
-
|
(947)
|
|
|
(947)
|
Total ordinary shares of 0.1p
each as at 31 December 2022
|
150,980,123
|
151
|
125,766
|
3,544
|
15,443
|
144,904
|
Issue of
ordinary shares as a result of warrants
|
2,794
|
-
|
-
|
-
|
-
|
-
|
Costs of
share issues
|
-
|
-
|
-
|
-
|
-
|
-
|
Total ordinary shares of 0.1p
each as at 31 December 2023
|
150,982,917
|
151
|
125,766
|
3,544
|
15,443
|
144,904
|
The Group undertook a share capital
reorganisation exercise during the year ended 31 December 2022,
splitting the ordinary shares with a nominal value of 15p into
ordinary shares of 0.1p and deferred shares of 14.9p. The new
deferred shares have no significant rights attached to them
and carry no right to vote or participate in distribution of
surplus assets and have not been admitted to trading on the AIM
market of the London Stock Exchange plc, nor will they in the
future. Accordingly, deferred shares are excluded from the
calculation of earnings per share.
|
|
|
Number
|
Total deferred shares of 14.9p each as at 31 December
2021
|
-
|
Issue of
deferred shares as part of share capital reorganisation
|
23,784,483
|
Total deferred shares of 14.9p each as at 31 December
2022
|
23,784,483
|
|
|
Total deferred shares of 14.9p each as at 31 December
2023
|
23,784,483
|
As permitted by the provisions of the Companies
Act 2006, the Company does not have an upper limit to its
authorised share capital.
The following is a summary of the changes in
the issued share capital of the Company during the period ended 31
December 2023:
(a) 2,794 ordinary shares of 0.1p per share
were allotted at a price of 5p per share, for total cash
consideration of £137 upon the exercise of warrants.
At 31 December 2023, the Company had two
classes of share, being ordinary shares of 0.1p each and deferred
shares of 14.9p each.
The Group's Share Capital reserve represents
the nominal value of the ordinary shares in issue. The Group's
Share Premium Reserve represents the premium the Group received on
issue if its shares. The Group's Deferred Share Capital reserve
represents the nominal value of the deferred shares in issue. The
Merger Reserve arose on the combination of companies within the
Group prior to the flotation on AIM.
As part of the placing completed in October
2022 the Group issued warrants to purchase ordinary shares of 0.1p
for a fixed fee of 5p per share. Following consultation with
warrant holders, the outstanding warrants were repriced to 2.85p
per share in December 2023. In addition, the warrant exercise lapse
date was amended to 31 January 2024. The warrant charge as
calculated based on this reprice was lower than the initial warrant
charge recognised on issue and hence no adjustment to the warrant
charge has been recognised in these financial
statements.
|
Number of
warrants
|
Weighted average exercise
price (p)
|
Weighted average contractual
life (years)
|
At 31
December 2021
|
-
|
-
|
-
|
Issued in
the period
|
127,195,640
|
5
|
1.5
|
At 31
December 2022
|
127,195,640
|
5
|
1.5
|
Exercised
in the period
|
(2,794)
|
5
|
1.5
|
Effect of
warrant reprice
|
-
|
(2.15)
|
(1.4)
|
At 31
December 2023
|
127,192,666
|
2.85
|
0.1
|
8) RELATED
PARTY TRANSACTIONS
During the year, the Group entered into
transactions, in the ordinary course of business, with other
related parties. Those transactions with directors are disclosed
below. Transactions entered into, along with trading balances
outstanding at each period end with other related parties, are as
follows:
|
|
Purchases from related
party
|
Amounts owed to related
party
|
Purchases
from related party
|
Amounts
owed to related party
|
|
|
31 December
|
31 December
|
31
December
|
31
December
|
|
|
2023
|
2023
|
2022
|
2022
|
Related
party
|
Relationship
|
£000
|
£000
|
£000
|
£000
|
|
|
|
|
|
|
IP Group
plc
|
Fund
manager for certain shareholders (note)
|
(4)
|
-
|
35
|
4
|
Cofra
London Limited
|
Shareholder
(note2)
|
15
|
15
|
-
|
-
|
|
|
|
|
|
|
Note: IP Group plc provide the services of
David Baynes, who was a director of the Company until 31 December
2022, and invoice the Group for related fees. David Baynes was a
Director of both the Company and of IP Group plc.
Note2: Cofra London Limited provide the
services of Donald Brenninkmeijer as a strategic advisor to the
Board, and invoice the Group for related fees.
Terms and
conditions of transactions with related parties
Purchases between related parties are made on
an arm's length basis. Outstanding balances are unsecured, interest
free and cash settlement is expected within 60 days of
invoice.
Transactions
with Key Management Personnel
The Company's key management personnel comprise
only the Directors of the Company. During the period, the Company
entered into the following transactions in which the Directors had
an interest:
Directors'
remuneration:
Remuneration received by the Directors from the
Company is set out below. Further detail is provided within the
Directors' remuneration report:
|
Year
|
Year
|
|
ended
|
Ended
|
|
31 December
|
31
December
|
|
2023
|
2022
|
|
£000
|
£000
|
Short-term employment benefits*
|
493
|
968
|
*In addition, certain Directors hold share
options in the Company for which a fair value share based charge of
£93,000 has been recognised in the consolidated statement of profit
or loss and other comprehensive income (year ended 31 December
2022: £93,000).
The highest-paid Director in the year received
a total remuneration of £262,000 (year ended 31 December 2022:
£405,000). During the year ended 31 December 2023, the Company
entered into numerous transactions with its subsidiary companies
which net off on consolidation - these have not been shown
above.
9) EVENTS
AFTER THE REPORTING PERIOD
Exercise of
warrants
Following the repricing of the Group's warrants
as approved by warrant holders on 21 December 2023, during the
revised warrant exercise period the Group received valid warrant
exercise notices for 58,913,935 warrants during January 2024. The
exercise of these warrants provided the Group with
£1,679,000.
Board
appointment
On 11 March 2024, the Group announced that Alex
Tristram, the Group's Finance Director, would join the
Board.
Placing and
Retail Offer
On 4 April 2024, the Group announced a placing
and retail offer to issue 310,789,561 new shares at 1.5p each. The
placing raised £4,662,000 for the Group, before fees.
10) PRIOR YEAR
RESTATEMENT
In the current year it was noted that,
the warrant reserve of £947,000 as created in 2023 was posted as
a debit balance within equity rather than as a credit balance
in error. As a result, and due to the material nature of the
balance, the prior year has been restated in these financial
statements. Given the nature of this restatement, there is no
impact in either net assets as at 31 December 2022 or on the
reported loss for the year ended 31 December 2022.
Forward-looking
statements
This announcement may include certain forward-looking
statements, beliefs or opinions, including statements with respect
to Xeros' business, financial condition and results of operations.
These forward-looking statements can be identified by the use of
forward-looking terminology, including the terms "believes",
"estimates", "plans", "anticipates", "targets", "aims",
"continues", "expects", "intends", "hopes", "may", "will", "would",
"could" or "should" or, in each case, their negative or other
various or comparable terminology. These statements are made by the
Xeros Directors in good faith based on the information available to
them at the date of this announcement and reflect the Xeros
Directors' beliefs and expectations. By their nature these
statements involve risk and uncertainty because they relate to
events and depend on circumstances that may or may not occur in the
future. A number of factors could cause actual results and
developments to differ materially from those expressed or implied
by the forward-looking statements, including, without limitation,
developments in the global economy, changes in government policies,
spending and procurement methodologies, and failure in health,
safety or environmental policies.
No
representation or warranty is made that any of these statements or
forecasts will come to pass or that any forecast results will be
achieved. Forward-looking statements speak only as at the date of
this announcement and Xeros and its advisers expressly disclaim any
obligations or undertaking to release any update of, or revisions
to, any forward-looking statements in this announcement. No
statement in the announcement is intended to be, or intended to be
construed as, a profit forecast or to be interpreted to mean that
earnings per Xeros share for the current or future financial years
will necessarily match or exceed the historical earnings. As a
result, you are cautioned not to place any undue reliance on such
forward-looking statements.